JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M905616199 on April 14, 2000

J. Biol. Chem., Vol. 275, Issue 30, 23106-23112, July 28, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/30/23106    most recent
M905616199v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laronga, C.
Right arrow Articles by Lee, M.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laronga, C.
Right arrow Articles by Lee, M.-H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Association of the Cyclin-dependent Kinases and 14-3-3 Sigma Negatively Regulates Cell Cycle Progression*

Christine LarongaDagger, Heng-Yin YangDagger, Christopher Neal, and Mong-Hong Lee§

From the Departments of Surgical Oncology/Molecular and Cellular Oncology and the Breast Cancer Research Program, the University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Received for publication, July 15, 1999, and in revised form, February 25, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

14-3-3 sigma, implicated in cell cycle arrest by p53, was cloned by expression cloning through cyclin-dependent kinase 2 (CDK2) association. 14-3-3 sigma shares cyclin-CDK2 binding motifs with different cell cycle regulators, including p107, p130, p21CIP1, p27KIP1, and p57KIP2, and is associated with cyclin·CDK complexes in vitro and in vivo. Overexpression of 14-3-3 sigma obstructs cell cycle entry by inhibiting cyclin-CDK activity in many breast cancer cell lines. Overexpression of 14-3-3 sigma can also inhibit cell proliferation and prevent anchorage-independent growth of these cell lines. These findings define 14-3-3 sigma as a negative regulator of the cell cycle progression and suggest that it has an important function in preventing breast tumor cell growth.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cyclin-dependent kinases (CDKs)1 are responsible for the transitions of the eukaryotic cell cycle and are tightly regulated by extra- and intracellular signals. They act in concert with their regulatory subunits, the cyclins, to facilitate the cell cycle progression. The cell cycle regulatory machinery is controlled by both positive and negative regulators. Cyclin-dependent kinases (CDKs) and their cyclin partners are positive regulators or accelerators that help cell cycle progression. The recently characterized cyclin-dependent kinase inhibitors (CKIs) are important negative regulators that act as brakes to stop cell cycle progression in response to regulatory signals (1). Two families of CKIs have been characterized based on the specificity of interaction with CDKs and sequence homology. The CIP/KIP family, which shares homology at the N-terminal CDK inhibitory domain, includes p21CIP1/WAF1 (2-5), p27KIP1 (6, 7), and p57KIP2 (8, 9). They interact with the cyclin·CDK complexes and inhibit the kinase activity of cyclin A-CDK2, cyclin D-CDK4, and cyclin E-CDK2. Overexpression of CIP/KIP inhibitors in cells can cause G1 arrest, suggesting that they preferentially target G1 cyclin·CDK complexes. The INK4 family includes p15 (INK4b) (10), p16 (INK4a) (11), p18 (INK4c) (12), and p19 (INK4d) (13). The INK4 family recognizes CDK4 and CDK6 but not CDK2 and may cause G1 arrest of the cell cycle by competing with cyclin D for binding with CDK4. Because the cell cycle regulatory machinery is such a complex system, it seems possible that more cell cycle regulators have yet to be discovered. Insights into the detailed regulation of the cell cycle machinery will help us understand the signals that render cells oncogenic. In order to understand the basic cell cycle regulatory machinery, we used an expression cloning method to search for CDK2-associated proteins and isolated a 14-3-3 protein.

The 14-3-3 proteins comprise a family of highly conserved acidic proteins, and there are at least seven different mammalian isoforms. Several activities have been ascribed to these proteins, including signal transduction of Raf-1 (14, 15) and cell cycle regulation (16, 17). However, the molecular mechanism behind cell cycle regulation has remained elusive. First, 14-3-3 epsilon and 14-3-3 beta have been isolated in a yeast two-hybrid screen designed to identify proteins that interact with the human CDC25A and CDC25B phosphatases. They bind to CDC25 but do not affect the phosphatase activities of CDC25 (18). Second, in a yeast two-hybrid screen designed to identify Wee1-associated proteins, the 14-3-3 zeta has been found to interact with the Wee1 kinase, which plays a key role in cell cycle progression by inactivating cyclin-dependent kinases (19). However, the binding of 14-3-3 zeta to Wee1 does not change the activity of Wee1 (19). Third, 14-3-3 has been shown to interact with polyoma middle T antigen (20) involved in cell proliferation, but it remains to be elucidated how regulation of 14-3-3 protein contributes to the development of neoplasia. Fourth, in yeast, two checkpoint genes, rad24 and rad25, encode 14-3-3 protein homologues that together provide a function that is essential for cell proliferation (16). The roles of RAD24 and RAD25 in regulating the activity of Chk1 or CDC25 in determining the progression of mitosis in response to DNA damage are not all clear (21, 22). Finally, 14-3-3 sigma (human mammary epithelial marker 1 or HME1) is expressed in epithelial cells, and its expression is dramatically low in human mammary carcinoma. However, its role in neoplastic formation is not understood (23). Furthermore, 14-3-3 sigma is induced by p53 in response to gamma irradiation and other DNA-damaging agents (24). 14-3-3 sigma induction results in a G2 arrest through an uncharacterized mechanism (24). Together, these observations imply that 14-3-3 proteins play important roles in cell cycle and that different 14-3-3 isoforms may bind to specific proteins for executing its biological function in cell cycle progression. Here, we describe the isolation, molecular cloning, and characterization of a CDK-associated protein 14-3-3 sigma. We show that 14-3-3 sigma could bind CDK2, CDC2, and CDK4 and emerges as a new class of CDK inhibitor.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression Cloning of 14-3-3 Sigma cDNA-- We prepared the FLAG-CDK2 following the procedure described before (8). Briefly, a PCR-generated NdeI-BamHI fragment of the human CDK2 cDNA containing the full-length coding region was subcloned into pET21a (Novagen), yielding a construct that encodes CDK2 with a FLAG tag sequence. Recombinant FLAG-CDK2 carrying the heart muscle kinase phosphorylation site was phosphorylated in vitro by protein kinase A with [gamma -32P]ATP following the procedure previously described (25). The phosphorylated CDK2 were used to screen a mouse 16-day embryonic library that is a T7 RNA polymerase-driven lambda EXlox mouse embryonic cDNA library (Novogen). At least 10 × 106 clones were screened. Several positive clones were sequenced, and one positive clone contained full-length c-DNA of mouse 14-3-3 sigma.

In Vitro Association of 14-3-3 Sigma and CDK Proteins-- A PCR-generated NdeI-BamHI fragment of the mouse 14-3-3 sigma cDNA containing the full-length coding region was subcloned into pET21a (Novagen) to yield a construct that encodes 14-3-3 sigma with a FLAG tag sequence. The protein was expressed in BL21(DE3), and FLAG-tagged proteins were prepared as described previously (8), except that proteins were immobilized on the beads without elution. Baculoviral proteins containing cyclins and CDKs were prepared by following the method described before (26). Cyclin D2 and CDK4 complex, cyclin B and CDC2 complex, or cyclin E and CDK2 complex was formed by preincubating in activating buffer (30 mM HEPES, 7.5 mM MgCl2, 40 mM phosphocreatine, 0.2 mg phosphocreatine kinase, 0.03 mM ATP). A T7 RNA polymerase-driven pET vector containing the coding region of the mouse cyclin E or CDK2 cDNA was transcribed in vitro and translated using a TNT kit (Promega). These products were labeled with [35S]methionine. These complexes, CDK, or the products translated in vitro were then incubated with the immobilized FLAG-tagged 14-3-3 sigma. After extensive washing in Nonidet P-40/RIPA buffer, the retained protein complexes were resuspended in SDS sample buffer. The complexes were resolved in SDS-polyacrylamide gel electrophoresis, followed by hybridization with CDK2 (PharMingen), CDK4 (PharMingen), and CDC2 antibody (Upstate Biotechnology Inc.) or by fluorography.

In Vivo Association of 14-3-3 Sigma with CDK-- MCF-7, HER-18, MDA-MB-468, MDA-MB-435, and MDA-MB-361 were kindly provided by Dr. Mien-Chi Hung and grown to 80% confluence. The cells were then infected with Ad-HME1 in serum-free media for 1 h. Complete media were added, and the cells were harvested 48 h later. The cells were lysed in RIPA buffer (100 mM NaCl, 20 mM Tris, pH 8.0, 1 mM EDTA, pH 8.0, 0.5% Triton X-100, 0.5% Nonidet P-40) and quantified with a Bio-Rad kit following the conditions suggested by the manufacturer. Equal amounts of total protein were immunoprecipitated with anti-CDK2 (1:1000) for 1 h followed by incubation with protein A beads for 30 min. After washing with lysis buffer, the proteins were loaded onto a 12% SDS-polyacrylamide gel and subjected to electrophoresis. Electrophoresed proteins were transferred to an Immobilon membrane (Millipore, Bedford, MA) and probed with anti-HA monoclonal antibody (12CA5, Babco). Immunocomplexes were visualized by chemiluminescence (ECL kit, Amersham Pharmacia Biotech) using goat anti-mouse IgG antibodies coupled with horseradish peroxidase (Amersham Pharmacia Biotech).

The CDK-associated Histone H1 Kinase Assay-- The cells were infected with Ad-HME1 in serum-free media for 1 h. Complete medium was added, and the cells were harvested 48 h later. The cells were lysed in RIPA lysis buffer (100 mM NaCl, 20 mM Tris, pH 8.0, 1 mM EDTA, pH 8.0, 0.5% Triton X-100, 0.5% Nonidet P-40) and quantified. 500 µg of cell lysate was immunoprecipitated with anti-CDK2 antibody (PharMingen) or anti-CDC2 antibody (PharMingen). The immunoprecipitates were assayed for histone H1 kinase activity as described previously (8).

MTT, Tridium-Thymidine Incorporation, and Soft Agar Colony Formation Assays-- MCF-7, HER-18, and MDA-MB-361 cells were infected with either Ad-HME1 or Ad-beta -galactosidase and compared with noninfected controls. The cells were harvested 48 h later, washed with phosphate-buffered saline, and trypsinized. By using the cell counter, 3000 cells/well (96 well plate) were seeded for each cell line and type of infection. This was replicated 7 times for serial time point measurements. Starting the following day and continuing daily for a total of 7 days, 50 µl of 4.8 mM MTT was added per well for 2 h. The cells were lysed with 200 µl of 100% Me2SO, and the absorbance at 570 nm reading was obtained using the 96-well plate reader (Ceres UV900C, Bio-Tek instruments Inc.). The absorbance is directly proportional to the number of cells.

A tridium-thymidine incorporation assay was performed using the same three cell lines and infection method as mentioned previously. Ten thousand cells per well were seeded for each cell line and type of infection in a 96-well plate. Six hours later, 0.2 µCi/well of tridium-thymidine was added and incubated for 16 h. Cells were lysed with 200 µl of 0.1 N KOH, and lysates were collected using the harvester (Tomtec). Tridium-thymidine incorporation was quantitated with the beta plate liquid scintillation counter (Amersham Pharmacia Biotech).

Soft agar colony assays were performed on the same three cell lines and under the same infection conditions. The following day, 2000 cells per well mixed in a 0.35% agarose/complete media suspension were seeded onto 0.7% agarose/complete media bottom layer. Three weeks later, 100 µl per well of p-iodonitrotetrazolium violet (1 mg/ml, Sigma) was added for 16 h before photographed.

Flow Cytometry-- Indicated breast cancer cell lines (MCF-7, HER-18, MDA-MB-453, and MDA-MB-468) were infected with or without Ad-HME1 (m.o.i. = 10). Forty-eight hours after infection, cells were sorted, and their DNA content was analyzed by flow cytometry, all as described (7).

Immunofluorescence-- NIH3T3 cells (2 × 105) were seeded onto chamber slides (Nunc) and infected without or with Ad-HME1 (m.o.i. = 10). R1b/L17 cells were transfected with pCMV5 plasmid containing FLAG-tagged HME1, FLAG-tagged HME1 (NES), T7-tagged-CDK2, or with empty vector. FLAG-tagged-HME1 (NES) is the NES mutant with point mutations (I205A and L208A) at the NES sequence (STLIMQLLRDNLTLW). This mutant was constructed by PCR mutation. T7-tagged CDK2 was constructed by PCR cloning to contain the T7 gene 10 leader peptide tag sequence (MASTGGQQMG). Twenty-four hours after infection or transfection, 2 × 105 cells were seeded onto tissue culture chamber slide (Nunc). Two days later, cells were fixed with methanol/acetone (1:1 v/v) and stained for 1 h with rabbit anti-CDK2, rabbit anti-CDC2 antibodies (Santa Crutz), mouse anti-FLAG monoclonal antibody (Sigma), or mouse anti-T7 monoclonal antibody (Novgen), followed by 30-min exposures to anti-rabbit Cy3-conjugated or anti-mouse fluorescein isothiocyanate-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories). Cells were then incubated with 0.1 µg/ml of 4,6-diamidino-2-phenylindole (DAPI) (Sigma) to stain the nuclei. Immunofluorescence was detected using a BX50 Fluorescent microscope (Olympus).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression Cloning of 14-3-3 Sigma-- The mouse 14-3-3 sigma gene was identified during a search for CDK2-associated proteins using an expression cloning method to screen a mouse 16-day embryonic cDNA library (27). Several clones were identified and sequenced. A GenBankTM search revealed that, at the amino acid level, one clone showed significantly high homology to human 14-3-3 sigma or HME1 (Human mammary epithelium marker 1) (23) and is the mouse ortholog of 14-3-3 sigma. The mouse 14-3-3 sigma (MME1) cDNA had an open reading frame of 744 base pairs, and it encodes a predicted protein of 248 amino acids. The human and mouse 14-3-3 sigma amino acid sequences are highly related, showing ~96% identity (Fig. 1A). Sequence analysis revealed an important feature of a leucine-rich nuclear exporting signal (NES) located at amino acids 202-216 (STLIMQLLRDNLTLW) that plays an important role in cell cycle regulation (22).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 1.   Mammalian 14-3-3 sigma sequences and cyclin-CDK2 recognition motif. A, alignment of 14-3-3 sigma amino acid sequences deduced from cDNA of mouse (MME1) and human (HME1). Identical amino acids are indicated by ellipses. The region of amino acid 202-216 contains a leucine-rich NES sequence. B, identification of a cyclin-CDK2 recognition motif present in MME1. Shown is the sequence alignment of cyclin-CDK2 binding motifs from different cell cycle regulators, including p107, p130, p21CIP1, p27KIP1, p57KIP2, and MME1. HME1 contains the exact recognition motif. p21CIP1 contains two such motifs, one at the N terminus (p21N) and one at the C terminus (p21C). The consensus sequence can be represented as (ZRXL), where Z and X, in most cases, are basic amino acids.

14-3-3 Sigma Contains the Cyclin-CDK Binding Motif-- Since we identified mouse 14-3-3 sigma using CDK2 as a bait through expression cloning, we compared the cyclin-CDK binding domain of all the important cell cycle regulatory proteins, including p27KIP1, p57KIP2, p21CIP1, p107, p130, and found that there is a consensus cyclin-CDK binding sequence (ZRXL, where Z and X are basic amino acids) that can be deduced in these proteins as shown in Fig. 1B. Structure determination of p27KIP1 has indicated that peptides around the ZRXL region are very critical for CDK binding (28). Therefore, 14-3-3 sigma is likely to use this CDK binding motif to interact with various CDKs.

14-3-3 Sigma Binds Cyclin-dependent Kinases-- To confirm further the binding of 14-3-3 sigma to cyclin-CDK2, recombinant FLAG-tagged 14-3-3 sigma protein was purified by M2 monoclonal antibody-Sepharose and used for in vitro biochemical binding assays. As shown in Fig. 2, 14-3-3 sigma can bind to CDK2, CDK4, cyclin A/CDK2, cyclin B/CDC2, cyclin E/CDK2, and cyclin D2/CDK4 specifically. 14-3-3 sigma also binds to in vitro translated cyclin E or CDK2. In order to confirm that 14-3-3 sigma interacts with CDK in vivo, we infected cells with recombinant adenovirus overexpressing HA-tagged 14-3-3 sigma, and we found that both CDC2 and CDK2 associated with 14-3-3 sigma, as demonstrated in the detection of CDK2 or CDC2 in the anti-HA immunoprecipitation complex (Fig. 3). Since CDKs are activated by their regulatory cyclins, we then tested the role of 14-3-3 sigma in this dynamic activating process. Affinity purified 14-3-3 sigma was used to test the binding character during the activating process of CDK2 by cyclin E. The data show that 14-3-3 sigma binds both active and inactive forms of CDK (Fig. 2E). These results provide evidence that 14-3-3 sigma does not block CDK activation, which is different from KIP1. KIP1 binds preactive cyclin E·CDK2 complexes and prevents Thr160 phosphorylation and activation of CDK2 (7).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 2.   CDK association by 14-3-3 sigma in vitro. A-C, 14-3-3 sigma associated with CDC2, CDK2, and CDK4. Recombinant FLAG-tagged 14-3-3 sigma was immobilized on the M2 beads. Insect cell lysates containing CDK2, CDC2, CDK4, and cyclins A, B, and D2 were incubated with the immobilized FLAG-tagged 14-3-3 sigma. After extensive washings, the retained protein complexes were detected by hybridization with CDK2, CDK4, and CDC2 antibodies, respectively. Immobilized FLAG-tagged 14-3-3 sigma beads were used as negative controls for each experiment (1st lane of each figure). Insect cell lysates containing CDK2, CDC2, or CDK4 were used as positive controls for immunoblotting (last lane of each figure). D, 14-3-3 sigma associated with in vitro translated cyclin E and CDK2. FLAG-tagged 14-3-3 sigma was bound to M2-Sepharose beads and was incubated with T7 RNA polymerase driven in vitro translated [35S]Met-labeled cyclin E or CDK2. - indicates the in vitro translated empty vector products and was used as negative binding controls. In vitro translated cyclin E and CDK2 proteins that were not incubated with FLAG-tagged 14-3-3 sigma beads were shown. E, 14-3-3 sigma binds to two forms of CDK2. FLAG-tagged 14-3-3 sigma was bound to M2-Sepharose beads and was incubated with equal amount of recombinant CDK2 (20 µg) plus an indicated amount of recombinant cyclin E (5 µg/µl). In the absence of other proteins, 14-3-3 sigma-bound Sepharose is used as a negative control. Cdk2* indicates the faster migrating form of CDK2 that corresponds to CDK2 phosphorylated at Thr160 and is the active form of CDK2.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3.   Mammalian expression of 14-3-3 sigma and its association with CDK2 and CDC2 in vivo. Ad-HME1-HA (+) and Ad-beta -galactosidase (-) were used to infect indicated breast cancer cell lines. Ad-HME1- and Ad-beta -galactosidase-infected cell lysates were immunoprecipitated by anti-CDK2 or anti-CDC2 antibody (PharMingen), resolved in SDS-polyacrylamide gel electrophoresis, and immunoblotted with anti-HA antibody (12CA5, Babco) to observe the association between 14-3-3 sigma and CDK2 or CDC2.

CDK Inhibitory Activity-- Most CDK-associated proteins can either negatively or positively regulate the activity of the CDKs. To investigate if 14-3-3 sigma can regulate the activity of the CDKs through protein association, we overexpressed 14-3-3 sigma in various cell lines by virus gene transfer (24), and we examined whether 14-3-3 sigma regulates the activity of CDKs. Recombinant 14-3-3 sigma adenovirus (Ad-HME1) was used to infect breast cancer cells under conditions in which the majority of the cell population was infected (m.o.i. = 10). The activity of both CDK2 and CDC2 was inhibited by the expression of 14-3-3 sigma as demonstrated in CDK2/CDC2-associated histone H1 kinase assays (Fig. 4). Also, immunoblotting bands demonstrate that when these cells were infected with Ad-HME1, HME1 associated with more than 95% of endogenous CDK2 or CDC2 as quantitated by PhosphorImager Imagequant program (data not shown), suggesting that 14-3-3 sigma can bind to most of the CDK2/CDC2 to inhibit their activities. All breast cancer cell lines tested were sensitive to the inhibitory activity of 14-3-3 sigma regardless of p53, Rb (retinoblastoma protein), or HER-2/neu status. These results provided evidence that 14-3-3 sigma can physically associate with CDKs and inhibit their activities. The inhibitory activity is also observed in a cell line with non-epithelial origin (NIH3T3) that does not express 14-3-3 sigma (data not shown).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   14-3-3 sigma inhibits CDK2- and CDC2-associated histone H1 kinase activities. Indicated equal amounts of cell lysates infected with Ad-HME1-HA (+) or Ad-beta -galactosidase (-) were assayed for CDK2-or CDC2-associated histone H1 (HH1) kinase activity. The phosphorylated histone H1 substrates are shown.

14-3-3 Sigma Overexpression Inhibits Cell Proliferation and Anchorage-independent Growth of Breast Cancer Cells-- The fact that 14-3-3 sigma can inhibit CDK activity suggests that 14-3-3 sigma may inhibit cell proliferation by cell cycle arrest. To determine if 14-3-3 sigma could inhibit cell proliferation, we assessed its inhibitory effect by MTT assay (29) and flow cytometry. Cell cycle analysis of several breast cancer cell lines infected with recombinant 14-3-3 sigma adenovirus by fluorescence-activated cell sorter demonstrated that 14-3-3 sigma has an effect on G2/M progression (Table I). Three breast cancer cell lines (MDA-MB-361, MCF7, and HER-18) were infected with recombinant 14-3-3 sigma adenovirus and assayed for live cells every 24 h. Overexpression of 14-3-3 sigma markedly decreased the viable cell number during a 7-day growth period as indicated by the decrease of A570 reading (Fig. 5A). In a parallel virus infection assay, the cells infected with adenovirus expressing beta -galactosidase (Ad-beta -galactosidase) grew normally as the cells that did not receive 14-3-3 sigma. Also, the rate of [3H]thymidine incorporation into DNA was reduced by half in cells infected with 14-3-3 sigma as compared with cells receiving no 14-3-3 sigma (Fig. 5B). Collectively, these results suggest that 14-3-3 sigma overexpression can prevent cell proliferation.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Effect of Hme1 on cell cycle distribution
Indicated breast cancer cell lines were infected with or without Ad-Hme1. Two days after infection, cells were collected in a cell sorter and subjected to flow cytometry to analyze the cell cycle distribution according to DNA content. Percent distribution in different cell cycle compartment is indicated.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 5.   Overexpression of 14-3-3 sigma blocks cell growth and cell cycle entry into S phase. The Ad-HME1-HA or Ad-beta -galactosidase (Ad-b-gal) was used to infect MCF7, HER-18, and MDA-MB-361 cell lines. Non-infected cells were used as controls. A, inhibitory effect of HME1 on cell growth. The cells were estimated by MTT assay every day for a total of 7 days. The results were expressed as the value of A570 reading. The absorbance is directly proportional to the number of cells. Bars, S.D. B, 14-3-3 sigma blocks cell cycle entry into S phase. [3H]Thymidine incorporation assays were conducted after 48 h infection. The experiments were repeated for three times. Data are expressed as percentage of [3H]thymidine incorporation relative to the controls of each cell line.

14-3-3 sigma was originally characterized as a molecule that was down-regulated in transformed breast carcinoma cell lines (23), suggesting that the activity of 14-3-3 sigma plays a pivotal role in the transformation. To evaluate the effect of 14-3-3 sigma on the transformation potency of the breast cancer cells, we performed the soft agar colony formation assays. As shown in Fig. 6, breast cancer cell lines (MCF-7 and HER-18) that received recombinant 14-3-3 sigma adenovirus had a dramatic decrease in the number of colonies formed after 3 weeks (Fig. 6). The cells infected with adenovirus expressing beta -galactosidase showed almost the same number of colonies as the cells that did not receive 14-3-3 sigma. Taken together, our data indicated that the transformed phenotypes of breast cancer cells can be reversed by overexpression of 14-3-3 sigma.


View larger version (73K):
[in this window]
[in a new window]
 
Fig. 6.   14-3-3 sigma decreased the transformation potency of the breast cancer cells. Two breast cancer cell lines, MCF7 and HER-18, were measured for their transformed properties in the presence of overexpression of HME1 as assayed by soft agar colony formation assay. Cells received no virus (control, A and D), adenovirus-expressing beta -galactosidase (Ad-Bgal, B and E), or HME1 (Ad-HME1, C and F) were seeded at 2 × 103 in 0.35% agarose containing Dulbecco's minimal essential medium with 10% calf serum. Colonies were counted and photographed 3 weeks later. The representative pictures from four independent experiments are shown here.

14-3-3 Sigma Inhibits Nuclear Accumulation of CDK2 and CDC2-- To support the hypothesis that interaction of 14-3-3 sigma and CDK proteins could have a physiological role, subcellular localization of these proteins was analyzed. As shown in Fig. 7, 14-3-3 sigma caused a decrease in the nuclear staining for both CDK2 and CDC2 compared with the controls. These results indicate that 14-3-3 sigma can sequester CDK2 and CDC2 from the nucleus, thereby preventing the activity of CDK2 and CDC2. Because 14-3-3 sigma contains a leucine-rich nuclear exporting signal at amino acid residues 202-216 (Fig. 1), we determined whether the nuclear accumulation of CDK2/CDC2 is mediated by the nuclear exporting activity of 14-3-3 sigma. An NES mutant of 14-3-3 sigma was constructed by mutating the leucine-rich NES sequence with alanine (I205A and L208A). Immunolocalization studies showed that wt 14-3-3 sigma was detected in the cytoplasm, whereas the NES mutant of 14-3-3 sigma was mainly detected in the nucleus (Fig. 8, A and C). We also found that CDK2 is distributed in the cytoplasm in the presence of wt 14-3-3 sigma (Fig. 8G), but CDK2 remains in the nucleus when coexpressed with the NES mutant of 14-3-3 sigma (Fig. 8I). CDK2 transfection was used as a control and was demonstrated as a nuclear protein (Fig. 8K). DAPI is used to stain the nuclei. These results demonstrated that the binding of 14-3-3 sigma to CDK can cause the sequestration of CDK2 and CDC2 into the cytoplasm, and the NES of 14-3-3 sigma is required for this biological function.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 7.   Subcellular localization of CDK2 and CDC2 is affected by overexpression of 14-3-3 sigma. The NIH3T3 cell lines were infected with (A-D) or without (E-H) Ad-HME1. After 48 h, cells were fixed and stained with anti-CDK2 (A and E) or anti-CDC2 antibodies (C and G) followed by Cy3-conjugated anti-rabbit immunoglobulin. Nuclei were stained with DAPI dye (B, D, F, and H).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 8.   14-3-3 sigma NES mutant cannot sequester CDK2 in the cytoplasm. R1b/L17 cells were transfected or co-transfected with indicated plasmids encoding wt HME1 (FLAG-HME1), HME1 NES mutant (FLAG-HME1 (NES)), or CDK2 (T7-CDK2). Empty vector transfection (CMV) was used as controls. After 48 h, cells were immunostained with anti-FLAG antibody for immunolocalization of HME1 (A, C, and E), or with anti-T7 antibody for immunolocalization of CDK2 (G, I, K, and M), followed by fluorescein isothiocyanate-conjugated anti-mouse immunoglobulin. The location of nuclei was indicated by DAPI staining (B, D, F, H, J, L, and N).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

New Class of CKI-- In a search for CDK2-associated proteins, we have identified a 14-3-3 protein, 14-3-3 sigma, that specifically associates with CDK2. 14-3-3 proteins are important and highly related dimeric factors found in eukaryotic organisms, including yeast, mammals, Drosophila, and plants (17). Members of the 14-3-3 family are involved in regulating the activities of tyrosine and tryptophan hydroxylases and protein kinase C, exocytosis, transcriptional activities, and the cell cycle (17). Here we demonstrated the specific interaction between CDKs and 14-3-3 sigma, and we characterized the biological functional role of the interaction in cell cycle progression. Interestingly, one CDK-like protein PCTAIRE-1 was shown to interact with several isoforms of 14-3-3, including eta, tau, and zeta isoforms (30). However, the significance of these interactions in cell cycle regulation remains to be determined. Sequence analysis showed that the 14-3-3 sigma protein is highly conserved with 96% identity in human and mouse. Its distinctive feature is a cyclin-CDK binding motif that is shared by many cyclin-CDK-binding proteins (Fig. 1), including CIP/KIP family members. In vitro binding experiments confirm that 14-3-3 sigma binds to various cyclin·CDK complexes (Fig. 2). Interestingly, purified 14-3-3 sigma cannot inhibit cyclin-CDK activity (data not shown) in vitro although overexpression of 14-3-3 sigma in the cells can inhibit CDK2/CDC2-associated kinase activity (Fig. 4) and cell cycle progression (Fig. 5), suggesting that a biological environment is required to assay its CDK inhibitory activity. Because it binds and inhibits various cyclin-CDKs to regulate cell cycle progression and cell proliferation, 14-3-3 sigma emerges as a new class of CKI.

CDK Inactivation and Growth Inhibition-- We showed that 14-3-3 sigma affects the subcellular localization of CDK2 and CDC2 to inhibit their accumulations in the nucleus, thus preventing the activation of CDK2/CDC2 in the nucleus. This mislocation of CDK2 and CDC2 in the cytoplasm can cause inhibition of their biological activities (31). Sequence analysis revealed a leucine-rich NES-like sequence (202STLIMQLLRDNLTLW212) in the 14-3-3 sigma. Indeed, we showed that 14-3-3 sigma can bind CDK proteins and sequester them in the cytoplasm (Fig. 7) through the nuclear exporting activities. The nuclear exporting sequence is involved in the sequestration of CDK2 since the NES mutant of 14-3-3 sigma cannot sequester the CDK2 into the cytoplasm (Fig. 8). Other 14-3-3 proteins have similar characteristics to export their target proteins to the cytoplasm, thus preventing their activities at the nucleus. For example, CDC25 is phosphorylated by Chk1 (32) or Chk2 (33) to create a binding site in CDC25 for 14-3-3 proteins and is exported by Rad24/Rad25 (also 14-3-3 proteins) in response to DNA damage (22), thereby inhibiting the activity of CDC25 and causing G2/M arrest. But it also remains to be determined which kinase is responsible for the serine phosphorylation on CDK2/CDC2 since targeted proteins of 14-3-3 required serine phosphorylation before binding to 14-3-3 (34). We demonstrated that 14-3-3 sigma can affect cell cycle distribution at the G2/M (Table I), which highlights its role at the G2/M control. The significance of the role of 14-3-3 sigma in inhibiting CDK2 activity and CDK2 nuclear accumulation remains to be determined in terms of cell cycle distribution and checkpoint control. However, both inhibition of CDC2-associated kinase activity and sequestering of CDC2 into the cytoplasm can account for its role in G2/M control.

Sequence analysis of human CDK2 reveals that there are two possible 14-3-3-binding sites located at the C-terminal region of CDK2 (GVTS229MP and YKPS236FP), which share a homologous sequence to what has been predicted as the 14-3-3 sigma-binding sites (35). Therefore, it is possible that 14-3-3 sigma may bind to this region to regulate CDK activities and cell cycle progression. Our data show that overexpression of 14-3-3 sigma in vivo could bind and inhibit the activities of CDK2 and CDC2 and render cells unable to reach cell cycle transition. In this aspect, it is functionally similar to the CIP/KIP family members. The strong reduction in the growth rate and the decrease in [3H]thymidine incorporation caused by 14-3-3 sigma expression are also consistent with a role of 14-3-3 sigma as a negative regulator of cell cycle. Through IR, 14-3-3 sigma was shown to be a mediator of p53 growth-inhibitory signaling (24). As cells received ionizing radiation, p53 quickly induced 14-3-3 sigma expression within 2 h, and this induction led to G2/M arrest (24). The mechanism behind this 14-3-3 sigma-induced cell cycle arrest is not clear, although it was proposed that 14-3-3 sigma may sequester CDC25C to cause G2 arrest (24) based on the observations that other 14-3-3 isoforms can interact with CDC25 (18, 36, 37). It remains to be elucidated if 14-3-3 sigma can interact with CDC25 directly to block G2/M progression in response to DNA damage. Our data show that 14-3-3 sigma can directly bind and sequester CDC2 into the cytoplasm to inhibit its activity required for G2/M progression, which may contribute to IR-induced p53-mediated G2/M arrest.

Inhibition of Cell Transformation-- After 14-3-3 sigma was cloned, it was determined that the expression level is significantly reduced both in v-Ha-Ras transformed mammary epithelial cells and mammary carcinoma cells (23). Furthermore, expression of 14-3-3 sigma was also reduced in SV40-transformed human keratinocytes compared with primary cells (38). Finally, the transcript of 14-3-3 sigma was down-regulated in head and neck squamous cell lines in comparison with keratinocytes (39). Together these observations support the idea that loss of its expression contributes to malignant transformation. Recent studies in breast carcinomas and colon cancer suggested that p27 expression is decreased when cells become tumorigenic (40-42). These observations lend further support to the concept that the CDK activity controls cell proliferation and is involved in the development of human cancer. The decreased expression of HME1 in neoplastic mammary cells is reminiscent of p27 down-regulation in breast cancer. We hypothesize that the expression of 14-3-3 sigma, like the function of p27KIP1, is one of the mechanisms cells employ to ensure the maintenance of a nonproliferative state. The fact that 14-3-3 sigma suppressed the anchorage-independent growth of some breast cancer cell lines (Fig. 6) supports the idea that loss of 14-3-3 sigma function correlates with cell transformation. Taken together, these results suggest that a reduction of 14-3-3 sigma plays an important role in cell transformation. Most significantly, fluorescence in situ hybridization analysis of metaphase chromosomes with a 14-3-3 sigma probe showed that 14-3-3 sigma was localized to chromosome 1p35 (24) where high percentages of loss of heterozygosity (43) were seen in different solid tumors including breast tumors (44). Also, on the basis of loss of heterozygosity and other data, 1p35 may harbor a tumor suppressor gene (45). The negative regulator role of 14-3-3 sigma in cell cycle progression and cell transformation suggests that 14-3-3 sigma could be the candidate for this tumor suppressor gene in the 1p35 region. Further investigation of the expression pattern and gene function of 14-3-3 sigma in tumors will shed light on its potential role as a tumor suppressor.

In summary, our characterization of 14-3-3 sigma as a CDK inhibitor will facilitate the study of its regulation and function in the cell cycle, its possible role as a tumor suppressor, and its possible implication in the gene transfer for p53-mutated cancer cells.

    ACKNOWLEDGEMENTS

We thank Drs. Hermeking and Vogelstein for valuable reagents; Drs. David Mentor and John Clifford for microscope help; Drs. Mein-Chie Hung, Ming-Jer Tsai, Sophia Tsai, and GiGi Lozano for critical reading; Rachel Z. Tsan, and Dr. Russell Berman for technical help.

    FOOTNOTES

* This work was supported by the William G. Mcgowan Charitable Foundation and by a Physician Referral Service grant from the University of Texas M. D. Anderson Cancer Center.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF152893.

Dagger Both authors contributed equally to this work.

§ Recipient of the Fleming and Davenport research award. To whom correspondence should be addressed: Box 18, the University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030. Tel.: 713-792-8741; Fax: 713-796-6059; E-mail: mhlee@notes.mdacc.tmc.edu.

Published, JBC Papers in Press, April 14, 2000, DOI 10.1074/jbc.M905616199

    ABBREVIATIONS

The abbreviations used are: CDKs, cyclin-dependent kinases; CKIs, cyclin-dependent kinase inhibitors; PCR, polymerase chain reaction; HA, hemagglutinin; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; DAPI, 4,6-diamidino-2-phenylindole; NES, nuclear exporting signal; m.o.i., multiplicity of infection; Ad, adenovirus; wt, wild type.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Sherr, C. J., and Roberts, J. M. (1995) Genes Dev. 9, 1149-1163
2. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. (1993) Nature 366, 701-704
3. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. (1993) Cell 75, 805-816
4. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993) Cell 75, 817-825
5. Gu, Y., Turck, C. W., and Morgan, D. O. (1993) Nature 366, 707-710
6. Toyoshima, H., and Hunter, T. (1994) Cell 78, 67-74
7. Polyak, K., Lee, M. H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., and Massague, J. (1994) Cell 78, 59-66
8. Lee, M. H., Reynisdottir, I., and Massague, J. (1995) Genes Dev. 9, 639-649
9. Matsuoka, S., Edwards, M. C., Bai, C., Parker, S., Zhang, P., Baldini, A., Harper, J. W., and Elledge, S. J. (1995) Genes Dev. 9, 650-662
10. Hannon, G. J., and Beach, D. (1994) Nature 371, 257-261
11. Serrano, M., Hannon, G. J., and Beach, D. (1993) Nature 366, 704-707
12. Guan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G., and Xiong, Y. (1994) Genes Dev. 8, 2939-2952
13. Guan, K. L., Jenkins, C. W., Li, Y., O'Keefe, C. L., Noh, S., Wu, X., Zariwala, M., Matera, A. G., and Xiong, Y. (1996) Mol. Biol. Cell 7, 57-70
14. Fantl, W. J., Muslin, A. J., Kikuchi, A., Martin, J. A., MacNicol, A. M., Gross, R. W., and Williams, L. T. (1994) Nature 371, 612-614
15. Li, S., Janosch, P., Tanji, M., Rosenfeld, G. C., Waymire, J. C., Mischak, H., Kolch, W., and Sedivy, J. M. (1995) EMBO J. 14, 685-696
16. Ford, J. C., Al-Khodairy, F., Fotou, E., Sheldrick, K. S., Griffiths, D. J., and Carr, A. M. (1994) Science 265, 533-535
17. Aitken, A., Collinge, D. B., van Heusden, B. P., Isobe, T., Roseboom, P. H., Rosenfeld, G., and Soll, J. (1992) Trends Biochem. Sci. 17, 498-501
18. Conklin, D. S., Galaktionov, K., and Beach, D. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7892-7896
19. Honda, R., Ohba, Y., and Yasuda, H. (1997) Biochem. Biophys. Res. Commun. 230, 262-265
20. Pallas, D. C., Fu, H., Haehnel, L. C., Weller, W., Collier, R. J., and Roberts, T. M. (1994) Science 265, 535-537
21. Chen, L., Liu, T. H., and Walworth, N. C. (1999) Genes Dev. 13, 675-685
22. Lopez-Girona, A., Furnari, B., Mondesert, O., and Russell, P. (1999) Nature 397, 172-175
23. Prasad, G. L., Valverius, E. M., McDuffie, E., and Cooper, H. L. (1992) Cell Growth Differ. 3, 507-513
24. Hermeking, H., Lengauer, C., Polyak, K., He, T. C., Zhang, L., Thiagalingam, S., Kinzler, K. W., and Vogelstein, B. (1997) Mol. Cell 1, 3-11
25. Margolis, B., Silvennoinen, O., Comoglio, F., Roonprapunt, C., Skolnik, E., Ullrich, A., and Schlessinger, J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8894-8898
26. Desai, D., Gu, Y., and Morgan, D. O. (1992) Mol. Biol. Cell 3, 571-582
27. Kaelin, W. G., Jr., Krek, W., Sellers, W. R., DeCaprio, J. A., Ajchenbaum, F., Fuchs, C. S., Chittenden, T., Li, Y., Farnham, P. J., Blanar, M. A., Livingston, D. M., and Flemington, E. K. (1992) Cell 70, 351-364
28. Russo, A. A., Jeffrey, P. D., Patten, A. K., Massague, J., and Pavletich, N. P. (1996) Nature 382, 325-331
29. Qiu, Y., Ravi, L., and Kung, H. J. (1998) Nature 393, 83-85
30. Sladeczek, F., Camonis, J. H., Burnol, A. F., and Le Bouffant, F. (1997) Mol. Gen. Genet. 254, 571-577
31. Pines, J. (1999) Nature 397, 104-105
32. Zeng, Y., Forbes, K. C., Wu, Z., Moreno, S., Piwnica-Worms, H., and Enoch, T. (1998) Nature 395, 507-510
33. Matsuoka, S., Huang, M., and Elledge, S. J. (1998) Science 282, 1893-1897
34. Muslin, A. J., Tanner, J. W., Allen, P. M., and Shaw, A. S. (1996) Cell 84, 889-897
35. Yaffe, M. B., Rittinger, K., Volinia, S., Caron, P. R., Aitken, A., Leffers, H., Gamblin, S. J., Smerdon, S. J., and Cantley, L. C. (1997) Cell 91, 961-971
36. Peng, C. Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., and Piwnica-Worms, H. (1997) Science 277, 1501-1505
37. Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., and Elledge, S. J. (1997) Science 277, 1497-1501
38. Dellambra, E., Patrone, M., Sparatore, B., Negri, A., Ceciliani, F., Bondanza, S., Molina, F., Cancedda, F. D., and De Luca, M. (1995) J. Cell Sci. 108, 3569-3579
39. Vellucci, V. F., Germino, F. J., and Reiss, M. (1995) Gene (Amst.) 166, 213-220
40. Porter, P. L., Malone, K. E., Heagerty, P. J., Alexander, G. M., Gatti, L. A., Firpo, E. J., Daling, J. R., and Roberts, J. M. (1997) Nat. Med. 3, 222-225
41. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M., and Pagano, M. (1997) Nat. Med. 3, 231-234
42. Catzavelos, C., Bhattacharya, N., Ung, Y. C., Wilson, J. A., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Morava-Protzner, I., Kapusta, L., Franssen, E., Pritchard, K. I., and Slingerland, J. M. (1997) Nat. Med. 3, 227-230
43. Nakayama, K., Ishida, N., Shirane, M., Inomata, A., Inoue, T., Shishido, N., Horii, I., Loh, D. Y., and Nakayama, K. (1996) Cell 85, 707-720
44. Ragnarsson, G., Eiriksdottir, G., Johannsdottir, J. T., Jonasson, J. G., Egilsson, V., and Ingvarsson, S. (1999) Br. J. Cancer 79, 1468-1474
45. Hilgers, W., Tang, D. J., Sugar, A. Y., Shekher, M. C., Hruban, R. H., and Kern, S. E. (1999) Genes Chromosomes Cancer 24, 351-355


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Arch Otolaryngol Head Neck SurgHome page
U. K. Bhawal, M. Sugiyama, Y. Nomura, H. Kuniyasu, and K. Tsukinoki
Loss of 14-3-3 Sigma Protein Expression and Presence of Human Papillomavirus Type 16 E6 in Oral Squamous Cell Carcinoma
Arch Otolaryngol Head Neck Surg, October 1, 2008; 134(10): 1055 - 1059.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
J. M. A. Moreira, T. Shen, G. Ohlsson, P. Gromov, I. Gromova, and J. E. Celis
A Combined Proteome and Ultrastructural Localization Analysis of 14-3-3 Proteins in Transformed Human Amnion (AMA) Cells: Definition of A Framework to Study Isoform-Specific Differences
Mol. Cell. Proteomics, July 1, 2008; 7(7): 1225 - 1240.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A.-L. Cheng, W.-G. Huang, Z.-C. Chen, F. Peng, P.-F. Zhang, M.-Y. Li, F. Li, J.-L. Li, C. Li, H. Yi, et al.
Identification of Novel Nasopharyngeal Carcinoma Biomarkers by Laser Capture Microdissection and Proteomic Analysis
Clin. Cancer Res., January 15, 2008; 14(2): 435 - 445.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
E. Marinova, S. Han, and B. Zheng
Human germinal center T cells are unique Th cells with high propensity for apoptosis induction
Int. Immunol., August 1, 2006; 18(8): 1337 - 1345.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
B. Han, H. Xie, Q. Chen, and J.-T. Zhang
Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3{sigma}.
Mol. Cancer Ther., April 1, 2006; 5(4): 903 - 912.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Yang, Y.-Y. Wen, R. Zhao, Y.-L. Lin, K. Fournier, H.-Y. Yang, Y. Qiu, J. Diaz, C. Laronga, and M.-H. Lee
DNA Damage-Induced Protein 14-3-3 {sigma} Inhibits Protein Kinase B/Akt Activation and Suppresses Akt-Activated Cancer.
Cancer Res., March 15, 2006; 66(6): 3096 - 3105.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Liu, H. Liu, B. Han, and J.-T. Zhang
Identification of 14-3-3{sigma} as a Contributor to Drug Resistance in Human Breast Cancer Cells Using Functional Proteomic Analysis.
Cancer Res., March 15, 2006; 66(6): 3248 - 3255.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
A. Wood and A. Shilatifard
Transcriptional blackjack with p21.
Genes & Dev., March 15, 2006; 20(6): 643 - 647.
[Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Yang, R. Zhao, and M.-H. Lee
14-3-3{sigma}, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma.
Mol. Cancer Ther., February 1, 2006; 5(2): 253 - 260.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
A. Benzinger, N. Muster, H. B. Koch, J. R. Yates III, and H. Hermeking
Targeted Proteomic Analysis of 14-3-3{varsigma}, a p53 Effector Commonly Silenced in Cancer
Mol. Cell. Proteomics, June 1, 2005; 4(6): 785 - 795.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Perathoner, D. Pirkebner, G. Brandacher, G. Spizzo, S. Stadlmann, P. Obrist, R. Margreiter, and A. Amberger
14-3-3{sigma} Expression Is an Independent Prognostic Parameter for Poor Survival in Colorectal Carcinoma Patients
Clin. Cancer Res., May 1, 2005; 11(9): 3274 - 3279.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
J. M. A. Moreira, G. Ohlsson, F. E. Rank, and J. E. Celis
Down-regulation of the Tumor Suppressor Protein 14-3-3{sigma} Is a Sporadic Event in Cancer of the Breast
Mol. Cell. Proteomics, April 1, 2005; 4(4): 555 - 569.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
T. Kino, A. Gragerov, A. Valentin, M. Tsopanomihalou, G. Ilyina-Gragerova, R. Erwin-Cohen, G. P. Chrousos, and G. N. Pavlakis
Vpr Protein of Human Immunodeficiency Virus Type 1 Binds to 14-3-3 Proteins and Facilitates Complex Formation with Cdc25C: Implications for Cell Cycle Arrest
J. Virol., March 1, 2005; 79(5): 2780 - 2787.
[Abstract] [Full Text] [PDF]